Vi­a­tris lands a court win over As­traZeneca, but gener­ics for block­buster in­haler still not ready to launch

It’s been 16 years since As­traZeneca’s block­buster asth­ma in­haler Sym­bi­cort came to mar­ket in the US, haul­ing in more than $13 bil­lion over just the last five years and be­com­ing the mar­ket leader in the in­haled cor­ti­cos­teroid/long-act­ing be­ta ag­o­nist class.

But ear­li­er this year, Vi­a­tris won FDA ap­proval for the first Sym­bi­cort gener­ic, known as Brey­na, open­ing up the po­ten­tial for cheap­er ver­sions of one of the most com­mon­ly pre­scribed com­plex drug-de­vice com­bo prod­ucts to treat asth­ma and COPD.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER